Ask AI
ProCE Banner Activity

BCMA Has Moved Upstream—Managed Care Strategy Must Follow

Clinical Thought

Gain expert insights through this ClinicalThought commentary for implementing BCMA-directed therapy into your care for patients with multiple myeloma, from treatment sequencing to toxicity management.

Released: May 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This educational activity is supported by independent medical education grants from GSK and Johnson & Johnson.

GSK

Johnson & Johnson

Target Audience

This activity is intended for oncology and managed care pharmacists and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the rationale for targeting BCMA in early R/R MM and analyze implications for formulary inclusion and treatment approaches to improve patient outcomes

  • Summarize recent updates on BCMA-targeted therapies for R/R MM, integrating these insights into internal clinical guidelines, formulary reviews, and patient/physician education

  • Develop and implement evidence-based strategies for monitoring and managing ocular toxicity with BCMA-targeted antibody–drug conjugates by establishing protocols, supporting coverage decisions, and facilitating multidisciplinary communication

  • Synthesize managed care perspectives when implementing BCMA-directed therapy in clinical practice

Disclosure

Primary Author

James A. Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, GSK, Janssen.

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP: consultant/advisor/speaker: Genentech, Genmab, GSK, Incyte, Johnson & Johnson, Lilly, Sanofi.

Anthony Perissinotti, PharmD, BCOP: consultant/advisor/speaker: Amgen, Jazz, Servier.